

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7057021

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the RECEIVING PARTY'S NAME TO INCLUDE MISSING PERIOD IN INC. previously recorded on Reel 058170 Frame 0751. Assignor(s) hereby confirms the ASSIGNMENT.
CONVEYING PARTY DATA	
Name	Execution Date
ROOPA RAI	01/25/2021
ROBERT BOOTH	01/25/2021
MICHAEL J. GREEN	01/25/2021
RECEIVING PARTY DATA	
Name:	MYOFORTE THERAPEUTICS, INC.
Street Address:	1455 ADAMS DRIVE
Internal Address:	SUITE 1293
City:	MENLO PARK
State/Country:	CALIFORNIA
Postal Code:	94025
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17484398
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 493-9300
Email:	melissa.sanchez@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	55773-708.301
NAME OF SUBMITTER:	MELISSA SANCHEZ
SIGNATURE:	/Melissa Sanchez/
DATE SIGNED:	12/06/2021
Total Attachments: 7	
source=Epirium Bio 55773-708.301 Notice of Recordation w- Assignment#page1.tif	

source=Epirium Bio 55773-708.301 Notice of Recordation w- Assignment#page2.tif
source=Epirium Bio 55773-708.301 Notice of Recordation w- Assignment#page3.tif
source=Epirium Bio 55773-708.301 Notice of Recordation w- Assignment#page4.tif
source=Epirium Bio 55773-708.301 Notice of Recordation w- Assignment#page5.tif
source=Epirium Bio 55773-708.301 Notice of Recordation w- Assignment#page6.tif
source=Epirium Bio 55773-708.301 Notice of Recordation w- Assignment#page7.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7035412

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ROOPA RAI	01/25/2021
ROBERT BOOTH	01/25/2021
MICHAEL J. GREEN	01/25/2021
RECEIVING PARTY DATA	
Name:	MYOFORTE THERAPEUTICS, INC
Street Address:	1455 ADAMS DRIVE
Internal Address:	SUITE 1293
City:	MENLO PARK
State/Country:	CALIFORNIA
Postal Code:	94025
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17484398
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 493-9300
Email:	melissa.sanchez@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	55773-708.301
NAME OF SUBMITTER:	MELISSA SANCHEZ
SIGNATURE:	/Melissa Sanchez/
DATE SIGNED:	11/19/2021
Total Attachments: 4	
source=Epirium Bio 55773-708.301 Executed Assignment Inventors (Parent)#page1.tif	
source=Epirium Bio 55773-708.301 Executed Assignment Inventors (Parent)#page2.tif	
source=Epirium Bio 55773-708.301 Executed Assignment Inventors (Parent)#page3.tif	

PATENT ASSIGNMENT

Docket Number: 52762-708 601

WHEREAS, the undersigned:

- | | | |
|---|---|---|
| 1. Roopa RAI
237 Clifton Avenue
San Carlos, California 94070
United States | 2. Robert BOOTH
26700 Shady Oaks Court
Los Altos Hills, California 94022
United States | 3. Michael J. GREEN
460 Balboa Boulevard
Half Moon Bay, California 94028
United States |
|---|---|---|

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

PGDH INHIBITORS AND METHODS OF MAKING AND USING

for which a PCT application PCT/US2021/014783 filed on 22 January 2021 in the U.S. Receiving Office of the Patent Cooperation Treaty which claiming priority to U.S. Application No. 62/965,062 filed 23 January 2020, U.S. Application No. 63/007,755 filed 9 April 2020, U.S. Application No. 63/029,184 filed 22 May 2020, U.S. Application No. 63/092,116 filed 15 October 2020, U.S. Application No. 63/110,803 filed 06 November 2020, and U.S. Application No. 63/133,965 filed 05 January 2021; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, MYOFORTE THERAPEUTICS, INC., a corporation incorporated under the laws of the State of Delaware, having a place of business at 1455 Adams Drive, Suite 1293, Menlo Park, California 94025, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)");

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee,

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of positions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below.

Date: <u>1-25-22</u>	<u>Roopa RAI</u>	Date: _____	_____
	Roopa RAI		Robert BOOTH
<hr/>			
Date: _____	_____	Date: _____	_____
	Michael J. GREEN		

PATENT ASSIGNMENT

Docket Number: 52762-708.601

WHEREAS, the undersigned:

1. Roopa RAI
237 Clifton Avenue
San Carlos, California 94070
United States

2. Robert BOOTH
26700 Shady Oaks Court
Los Altos Hills, California 94022
United States

3. Michael J. GREEN
400 Balboa Boulevard
Half Moon Bay, California 94025
United States

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

PGDH INHIBITORS AND METHODS OF MAKING AND USING

for which a PCT application PCT/US2021/014783 filed on 22 January 2021 in the U.S. Receiving Office of the Patent Cooperation Treaty which claiming priority to U.S. Application No. 63/965,062 filed 23 January 2020; U.S. Application No. 63/007,755, filed 2 April 2020; U.S. Application No. 63/029,184, filed 22 May 2020; U.S. Application No. 63/092,116, filed 15 October 2020; U.S. Application No. 63/110,803, filed 06 November 2020; and U.S. Application No. 63/133,965, filed 05 January 2021; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, MYOFORTE THERAPEUTICS, INC., a corporation incorporated under the laws of the State of Delaware, having a place of business at 1455 Adams Drive, Suite 1293, Menlo Park, California 94025, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Roopa RAI

Date: Jan 25, 2021
Robert BOOTH

Date: _____
Michael J. GREEN

PATENT ASSIGNMENT

Docket Number: 52762-708.601

WHEREAS, the undersigned:

1. Roopa RAI
237 Clifton Avenue
San Carlos, California 94070
United States
2. Robert BOOTH
26700 Shady Oaks Court
Los Altos Hills, California 94022
United States
3. Michael J. GREEN
400 Balboa Boulevard
Half Moon Bay, California 94025
United States

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

PCDH INHIBITORS AND METHODS OF MAKING AND USING

for which a PCT application PCT/US2021/014793 filed on 22 January 2021 in the U.S. Receiving Office of the Patent Cooperation Treaty which claiming priority to U.S. Application No. 62/965,062 filed 23 January 2020; U.S. Application No. 63/007,755, filed 2 April 2020; U.S. Application No. 63/029,184, filed 22 May 2020; U.S. Application No. 63/092,116, filed 15 October 2020; U.S. Application No. 63/110,803, filed 06 November 2020; and U.S. Application No. 63/133,965, filed 05 January 2021; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).


WHEREAS, MYOFORTE THERAPEUTICS, INC., a corporation incorporated under the laws of the State of Delaware, having a place of business at 1455 Adams Drive, Suite 1293, Menlo Park, California 94025, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____	_____	Date: _____	_____
	Roopa RAI		Robert BOOTH
Date: <u>01/25/21</u>	<u>Michael J. Green</u>		
	Michael J. GREEN		

PATENT ASSIGNMENT		Docket Number: 52762-708.601
RECEIVED AND AGREED TO BY ASSIGNEE: MYOFORTE THERAPEUTICS, INC.		
Date: <u>1/28/21</u>	Signature: <u></u>	
	Name: <u>VIVEK SHEKHAR</u>	
	Title: <u>PRESIDENT & COO</u>	